Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05163080 |
|---|---|
| Brief Title: | SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) (SURVIVE) |
| First Submitted : | December 6, 2021 |
| First Submitted that Met QC Criteria : | December 6, 2021 |
| First Posted : | December 20, 2021 |
| Last Update Submitted that Met QC Criteria : | February 23, 2024 |
| Last Update Posted : | February 26, 2024 |